Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,820.00-0.06%ETH$2,284.00+0.76%GOLD$3,913.10+0.36%OIL$99.40-4.53%
Smart Investors Daily
SID Premium
VN

AMEX · VNRX

VolitionRx Limited

Healthcare · Medical - Diagnostics & Research

$0.20

Down-$0.00 (-1.11%)

Updated Nov 2, 2026, 11:44 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.3M
P/E ratio
-1.34
Dividend yield
0.00%
52-week range
$0.16 – $9.50
Volume
1.06M
Avg. volume
1.34M

Price performance · VNRX

VNRX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

VNRX closed at $0.20 after 20 trading sessions, down 15.82% for the selected period.

Last close
$0.20
Period change
-15.82%
Period low
$0.17
Period high
$0.24
Daily close
View OHLC price history
VNRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.20$0.2003$0.183$0.19531.06M
Oct 29, 2026$0.1843$0.20$0.173$0.19751.09M
Oct 28, 2026$0.19$0.1924$0.1707$0.18181.25M
Oct 27, 2026$0.19$0.1927$0.1601$0.1853.98M
Oct 26, 2026$0.175$0.1804$0.1739$0.1786610.92K
Oct 23, 2026$0.1652$0.1783$0.1652$0.1741509.19K
Oct 22, 2026$0.1652$0.171$0.1564$0.16911.68M
Oct 21, 2026$0.17$0.1726$0.1642$0.1664494.72K
Oct 20, 2026$0.1699$0.1788$0.1627$0.1732593.17K
Oct 19, 2026$0.1795$0.1819$0.1676$0.17381.18M
Oct 16, 2026$0.1905$0.191$0.1801$0.1801492.73K
Oct 15, 2026$0.18$0.194$0.178$0.18851.43M
Oct 14, 2026$0.183$0.183$0.1748$0.179993.18K
Oct 13, 2026$0.2011$0.207$0.18$0.18471.84M
Oct 12, 2026$0.216$0.216$0.2011$0.2031777.56K
Oct 9, 2026$0.2223$0.23$0.2113$0.21131.08M
Oct 8, 2026$0.2269$0.2331$0.2165$0.2194825.47K
Oct 7, 2026$0.2396$0.2406$0.2204$0.2261.36M
Oct 6, 2026$0.233$0.2474$0.2321$0.2429644.26K
Oct 5, 2026$0.2342$0.2429$0.2317$0.232716.93K

Latest VNRX news

The latest Smart Investors Daily articles mentioning VNRX.

Stock researchCompany · Overview

VNRX research

Overview

Company profile and research snapshot.

Company profile

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
VNRX recent ratings
DateFirmRatingTarget
Jun 18, 2026Maxim GroupBuy—
Apr 20, 2026D. Boral CapitalHold—
Apr 2, 2026HC Wainwright & Co.Buy—
Mar 31, 2026D. Boral CapitalBuy—
Mar 26, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent ("LOI") with Missionpharma A/S, a Danish global leader in the sale and distribution of healthcare products and innovative solutions, impacting the lives of over 100 million patients annually, regarding the potential development and launch of Volition's prototype Lateral Flow Technology ("LFT") for NETosis.

Yahoo · Oct 27, 2026

VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a $500,000 partial prepayment in cash towards the outstanding principal balance on its senior secured convertible promissory note, dated January 15, 2026, in the original principal amount of $2,400,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the partial pre-payment, the remaining outstanding balance under the Note as of the date of this announcemen

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By